A Roundtable Discussion on Regenerative Medicine
From our February 1 issue: Scientists...
From our February 1 issue: Better...
From our February 1 issue: A...
For full access to this article login to GEN Select now.
Most 2013 deals involved big biotechs, and even several big pharmas, snapping up smaller biopharmas. [© Yuri Arcurs - Fotolia.com]
Following is a list of the 25 largest merger and acquisition (M&A) deals disclosed in 2013 by drug developers, tools/tech companies, and CROs, ranked ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
How should consent terms reconcile donors’ moral concerns with biobanks’ research goals?
Be sure to add firstname.lastname@example.org
to your Address Book or Safe Senders List.
here for instructions.
If you have any questions about your subscription, click
here to email us or call at (914) 740-2189.
You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
© 2015 Genetic Engineering & Biotechnology News All Rights Reserved